Is APGE or PURR more profitable?

Apogee Therapeutics' return on equity of -32.64% beat Hyperliquid Strategies' return on equity. Company Net Margins Return on Equity Return on Assets Apogee Therapeutics N/A -32.64% -31.25% Hyperliquid Strategies N/A -56.04% -52.22%

Is CGON or PURR more profitable?

CG Oncology's return on equity of -23.33% beat Hyperliquid Strategies' return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% Hyperliquid Strategies N/A -56.04% -52.22%

Hyperliquid Strategies (PURR) Competitors

$8.74 +0.72 (+8.98%)

Closing price 04:00 PM Eastern

Extended Trading

$8.66 -0.08 (-0.92%)

As of 07:59 PM Eastern

Compare

PURR vs. TWST, APGE, CGON, GRFS, and AMRX

Should you buy Hyperliquid Strategies stock or one of its competitors? MarketBeat compares Hyperliquid Strategies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hyperliquid Strategies include Twist Bioscience (TWST), Apogee Therapeutics (APGE), CG Oncology (CGON), Grifols (GRFS), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry.

How does Hyperliquid Strategies compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Hyperliquid Strategies (NASDAQ:PURR) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Twist Bioscience presently has a consensus price target of $74.60, suggesting a potential downside of 25.28%. Hyperliquid Strategies has a consensus price target of $9.25, suggesting a potential upside of 5.84%. Given Hyperliquid Strategies' higher possible upside, analysts plainly believe Hyperliquid Strategies is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Twist Bioscience has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market.

Hyperliquid Strategies has lower revenue, but higher earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	16.51	-$77.67M	-$1.33	N/A
Hyperliquid Strategies	$1M	1,262.49	-$16.01M	-$7.37	N/A

In the previous week, Twist Bioscience had 7 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 10 mentions for Twist Bioscience and 3 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.51 beat Twist Bioscience's score of 0.31 indicating that Hyperliquid Strategies is being referred to more favorably in the news media.

Company	Overall Sentiment
Twist Bioscience	Neutral
Hyperliquid Strategies	Positive

Hyperliquid Strategies has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Twist Bioscience's return on equity of -26.73% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

9.5% of Hyperliquid Strategies shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by company insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Twist Bioscience and Hyperliquid Strategies tied by winning 8 of the 16 factors compared between the two stocks.

How does Hyperliquid Strategies compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Hyperliquid Strategies (NASDAQ:PURR) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Apogee Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market.

Apogee Therapeutics' return on equity of -32.64% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

Hyperliquid Strategies has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Hyperliquid Strategies	$1M	1,262.49	-$16.01M	-$7.37	N/A

In the previous week, Apogee Therapeutics had 40 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 43 mentions for Apogee Therapeutics and 3 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.51 beat Apogee Therapeutics' score of 0.18 indicating that Hyperliquid Strategies is being referred to more favorably in the news media.

Company	Overall Sentiment
Apogee Therapeutics	Neutral
Hyperliquid Strategies	Positive

Apogee Therapeutics currently has a consensus price target of $121.25, indicating a potential downside of 8.52%. Hyperliquid Strategies has a consensus price target of $9.25, indicating a potential upside of 5.84%. Given Hyperliquid Strategies' stronger consensus rating and higher possible upside, analysts clearly believe Hyperliquid Strategies is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of Hyperliquid Strategies shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Apogee Therapeutics beats Hyperliquid Strategies on 8 of the 15 factors compared between the two stocks.

How does Hyperliquid Strategies compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Hyperliquid Strategies (NASDAQ:PURR) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

CG Oncology has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market.

CG Oncology currently has a consensus price target of $81.73, suggesting a potential upside of 13.57%. Hyperliquid Strategies has a consensus price target of $9.25, suggesting a potential upside of 5.84%. Given CG Oncology's stronger consensus rating and higher probable upside, analysts plainly believe CG Oncology is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

CG Oncology's return on equity of -23.33% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 9.5% of Hyperliquid Strategies shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, CG Oncology had 2 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 5 mentions for CG Oncology and 3 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.51 beat CG Oncology's score of 0.34 indicating that Hyperliquid Strategies is being referred to more favorably in the news media.

Company	Overall Sentiment
CG Oncology	Neutral
Hyperliquid Strategies	Positive

Hyperliquid Strategies has lower revenue, but higher earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$5.07M	1,251.63	-$160.99M	-$2.33	N/A
Hyperliquid Strategies	$1M	1,262.49	-$16.01M	-$7.37	N/A

Summary

CG Oncology beats Hyperliquid Strategies on 9 of the 15 factors compared between the two stocks.

How does Hyperliquid Strategies compare to Grifols?

Hyperliquid Strategies (NASDAQ:PURR) and Grifols (NASDAQ:GRFS) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Grifols has a net margin of 5.54% compared to Hyperliquid Strategies' net margin of 0.00%. Grifols' return on equity of 6.21% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Grifols	5.54%	6.21%	2.39%

In the previous week, Grifols had 1 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 4 mentions for Grifols and 3 mentions for Hyperliquid Strategies. Grifols' average media sentiment score of 0.69 beat Hyperliquid Strategies' score of 0.51 indicating that Grifols is being referred to more favorably in the news media.

Company	Overall Sentiment
Hyperliquid Strategies	Positive
Grifols	Positive

Grifols has higher revenue and earnings than Hyperliquid Strategies. Hyperliquid Strategies is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	1,262.49	-$16.01M	-$7.37	N/A
Grifols	$8.51B	0.59	$454.82M	$0.19	39.08

Hyperliquid Strategies presently has a consensus target price of $9.25, indicating a potential upside of 5.84%. Grifols has a consensus target price of $10.00, indicating a potential upside of 34.68%. Given Grifols' higher possible upside, analysts plainly believe Grifols is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Grifols	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Hyperliquid Strategies has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market. Comparatively, Grifols has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

9.5% of Hyperliquid Strategies shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by insiders. Comparatively, 0.2% of Grifols shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Grifols beats Hyperliquid Strategies on 10 of the 16 factors compared between the two stocks.

How does Hyperliquid Strategies compare to Amneal Pharmaceuticals?

Hyperliquid Strategies (NASDAQ:PURR) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

9.5% of Hyperliquid Strategies shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Hyperliquid Strategies currently has a consensus target price of $9.25, indicating a potential upside of 5.84%. Amneal Pharmaceuticals has a consensus target price of $15.80, indicating a potential downside of 8.30%. Given Hyperliquid Strategies' higher probable upside, research analysts clearly believe Hyperliquid Strategies is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Hyperliquid Strategies has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

Amneal Pharmaceuticals has higher revenue and earnings than Hyperliquid Strategies. Hyperliquid Strategies is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	1,262.49	-$16.01M	-$7.37	N/A
Amneal Pharmaceuticals	$3.02B	1.82	$72.06M	$0.38	45.34

In the previous week, Amneal Pharmaceuticals had 2 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 5 mentions for Amneal Pharmaceuticals and 3 mentions for Hyperliquid Strategies. Amneal Pharmaceuticals' average media sentiment score of 0.60 beat Hyperliquid Strategies' score of 0.51 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Hyperliquid Strategies	Positive
Amneal Pharmaceuticals	Positive

Amneal Pharmaceuticals has a net margin of 4.01% compared to Hyperliquid Strategies' net margin of 0.00%. Hyperliquid Strategies' return on equity of -56.04% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%

Summary

Amneal Pharmaceuticals beats Hyperliquid Strategies on 12 of the 16 factors compared between the two stocks.

Get Hyperliquid Strategies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PURR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PURR vs. The Competition

Export

Metric	Hyperliquid Strategies	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.16B	$2.93B	$4.35B	$12.24B
Dividend Yield	N/A	15.31%	12.96%	6.10%
P/E Ratio	-1.19	13.53	21.95	24.18
Price / Sales	1,262.49	2,912.34	159.52	102.02
Price / Cash	N/A	25.92	38.27	54.37
Price / Book	5.75	4.85	13.62	6.35
Net Income	-$16.01M	-$34.85M	$115.37M	$337.63M
7 Day Performance	-5.82%	-1.12%	-1.12%	-0.30%
1 Month Performance	3.43%	-1.53%	-2.51%	0.36%
1 Year Performance	N/A	12.10%	10.88%	26.94%

Hyperliquid Strategies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PURR Hyperliquid Strategies	1.504 of 5 stars	$8.74 +9.0%	$9.25 +5.8%	N/A	$1.16B	$1M	N/A	N/A	Options Volume
TWST Twist Bioscience	1.4079 of 5 stars	$84.95 +5.1%	$71.60 -15.7%	+161.3%	$5.29B	$409.48M	N/A	990	Analyst Forecast Insider Trade
APGE Apogee Therapeutics	1.3576 of 5 stars	$85.24 -1.1%	$114.56 +34.4%	+208.6%	$5.28B	N/A	N/A	91	Analyst Downgrade Insider Trade Options Volume
CGON CG Oncology	2.143 of 5 stars	$60.28 +1.2%	$81.73 +35.6%	+179.5%	$5.25B	$4.04M	N/A	61	Positive News Insider Trade Gap Down
GRFS Grifols	4.5417 of 5 stars	$7.59 -0.4%	$10.00 +31.8%	-13.4%	$5.19B	$8.51B	39.95	25,247	Dividend Announcement Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PURR) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hyperliquid Strategies (PURR) Competitors

PURR vs. TWST, APGE, CGON, GRFS, and AMRX

How does Hyperliquid Strategies compare to Twist Bioscience?

Summary

How does Hyperliquid Strategies compare to Apogee Therapeutics?

Summary

How does Hyperliquid Strategies compare to CG Oncology?

Summary

How does Hyperliquid Strategies compare to Grifols?

Summary

How does Hyperliquid Strategies compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PURR vs. The Competition

Hyperliquid Strategies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hyperliquid Strategies (PURR) Competitors

PURR vs. TWST, APGE, CGON, GRFS, and AMRX

How does Hyperliquid Strategies compare to Twist Bioscience?

Do analysts rate TWST or PURR?

Which has more volatility & risk, TWST or PURR?

Which has better earnings & valuation, TWST or PURR?

Does the media refer more to TWST or PURR?

Is TWST or PURR more profitable?

Do institutionals and insiders hold more shares of TWST or PURR?

Summary

How does Hyperliquid Strategies compare to Apogee Therapeutics?

Which has more risk and volatility, APGE or PURR?

Is APGE or PURR more profitable?

Which has higher earnings and valuation, APGE or PURR?

Does the media refer more to APGE or PURR?

Do analysts prefer APGE or PURR?

Do institutionals & insiders believe in APGE or PURR?

Summary

How does Hyperliquid Strategies compare to CG Oncology?

Which has more volatility and risk, CGON or PURR?

Do analysts rate CGON or PURR?

Is CGON or PURR more profitable?

Do insiders and institutionals hold more shares of CGON or PURR?

Does the media favor CGON or PURR?

Which has better valuation and earnings, CGON or PURR?

Summary

How does Hyperliquid Strategies compare to Grifols?

Is PURR or GRFS more profitable?

Does the media prefer PURR or GRFS?

Which has preferable valuation and earnings, PURR or GRFS?

Do analysts prefer PURR or GRFS?

Which has more risk & volatility, PURR or GRFS?

Do institutionals and insiders have more ownership in PURR or GRFS?

Summary

How does Hyperliquid Strategies compare to Amneal Pharmaceuticals?

Do insiders and institutionals believe in PURR or AMRX?

Do analysts recommend PURR or AMRX?

Which has more volatility & risk, PURR or AMRX?

Which has higher earnings and valuation, PURR or AMRX?

Does the media refer more to PURR or AMRX?

Is PURR or AMRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PURR vs. The Competition

Hyperliquid Strategies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools